Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123-32. doi: 10.1038/ni1254.
Sabat R, Witte E, Witte K, Wolk K. IL-22 and IL-17: An overview. In: Valérie Quesniaux V, Bernhard Ryffel B, Franco Padova F, editors. IL-17, IL-22 and their producing cells: Role in inflammation and autoimmunity. Progress in Inflammation Research. Springer, Basel; 2013. 11-35 p. doi: 10.1007/978-3-0348-0522-3_2.
Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother. 2018 May;101:287-292. doi: 10.1016/j.biopha.2018.02.103.
Zak KP, Tron'ko ND, Popova VV, Butenko AK. Diabetes mellitus, Immunity, Cytokines. Kyiv: Kniga plyus; 2015. 485 p. (in Ukrainian).
Marwaha AK, Crome SQ, Panagiotopoulos C, Berg KB, Qin H, Ouyang Q, et al. Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J Immunol. 2010 Oct 1;185(7):3814-8. doi: 10.4049/jimmunol.1001860.
Ferraro A, Socci C, Stabilini A, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes. 2011 Nov;60(11):2903-13. doi: 10.2337/db11-0090.
Martin-Orozco N, Chung Y, Chang SH, Wang Y-H, Dong Ch. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol. 2009 Jan;39(1):216-24. doi: 10.1002/eji.200838475.
Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A, Shapiro AM. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes. 2009 Jun;58(6):1302-11. doi: 10.2337/db08-1113.
Kuriya G, Uchida T, Akazawa S, et al. Double deficiency in IL-17 and IFN-г signalling significantly suppresses the development of diabetes in the NOD mouse. Diabetologia. 2013 Aug;56(8):1773-80. doi: 10.1007/s00125-013-2935-8.
Bending D, De la Peсa H, Veldhoen M, et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest. 2009 Mar;119(3):565-72. doi: 10.1172/JCI37865.
Vukkadapu SS, Belli JM, Ishii K, et al. Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genomics. 2005 Apr 14;21(2):201-11. doi: 10.1152/physiolgenomics.00173.2004.
Azuma MM, Gomes-Filho JE, Prieto AKC, et al. Diabetes increases interleukin-17 levels in periapical, hepatic, and renal tissues in rats. Arch Oral Biol. 2017 Nov;83:230-235. doi: 10.1016/j.archoralbio.2017.08.001.
Roohi A, Tabrizi M, Abbasi F, et al. Serum IL-17, IL-23, and TGF-в levels in type 1 and type 2 diabetic patients and age-matched healthy controls. Biomed Res Int. 2014;2014:718946. doi: 10.1155/2014/718946.
Bradshaw EM, Raddassi K, Elyaman W, et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol. 2009 Oct 1;183(7):4432-9. doi: 10.4049/jimmunol.0900576.
Honkanen JK, Nieminen JK, Skarsvik S, et al. Coxsackievirus up-regulates IL-17 immunity in human type 1 diabetes: A-421. In: Abstracts of the 47th Annual Meeting of the EASD, Lisbon 2011. Diabetologia. 2011;54(Suppl 1):S1-S542. doi: 10.1007/s00125-011-2276-4.
Arif S, Moore F, Marks K, et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated в-cell death. Diabetes. 2011 Aug;60(8):2112-9. doi: 10.2337/db10-1643.
Zak KP, Furmanova OV. Immune and anti-inflammatory factors in the mechanism of therapeutic effect of metformin in type 2 diabetes mellitus (analytical review including the results of own researches) Mìžnarodnij endokrinologìčnij žurnal. 2018;14(2):173-181. doi: 10.22141/2224-07184.108.40.2068.130564 (in Ukrainian).
Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes - considerations for attempts to prevent and reverse the disease. Diabetes Care. 2015 Jun;38(6):979-88. doi: 10.2337/dc15-0144.
Kumar P, Natarajan K, Shanmugam N. High glucose driven expression of pro-inflammatory cytokine and chemokine genes in lymphocytes: molecular mechanisms of IL-17 family gene expression. Cell Signal. 2014 Mar;26(3):528-39. doi: 10.1016/j.cellsig.2013.11.031.
Tripathi D, Cheekatla SS, Paidipally P, et al. c-Jun N-terminal kinase 1 defective CD4+CD25+FoxP3+ cells prolong islet allograft survival in diabetic mice. Sci Rep. 2018 Feb 19;8(1):3310. doi: 10.1038/s41598-018-21477-9.
Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006 May 11;441(7090):235-8. doi: 10.1038/nature04753.
Fatima N, Faisal SM, Zubair S, Siddiqui SS, Moin S, Owais M. Emerging role of Interleukins IL-23/IL-17 axis and biochemical markers in the pathogenesis of type 2 diabetes: Association with age and gender in human subjects. Int J Biol Macromol. 2017 Dec;105(Pt 1):1279-1288. doi: 10.1016/j.ijbiomac.2017.07.155.
Sunandhakumari JV, Sadasivan A, Koshi E, Krishna A, Alim A, Sebastian A. Effect of nonsurgical periodontal therapy on plasma levels of IL-17 in chronic periodontitis patients with well controlled type-II diabetes mellitus – a clinical study. Dent J (Basel). 2018 Jun 13;6(2). pii: E19. doi: 10.3390/dj6020019.
Zhang C, Xiao C, Wang P, et al. The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Hum Immunol. 2014 Apr;75(4):289-96. doi: 10.1016/j.humimm.2014.02.007.
Borilova Linhartova P, Kastovsky J, Lucanova S, et al. Interleukin-17A gene variability in patients with type 1 diabetes mellitus and chronic periodontitis: Its correlation with IL-17 levels and the occurrence of Periodontopathic Bacteria. Mediators Inflamm. 2016;2016:2979846. doi: 10.1155/2016/2979846.
Miranda TS, Heluy SL, Cruz DF, et al. The ratios of pro-inflammatory to anti-inflammatory cytokines in the serum of chronic periodontitis patients with and without type 2 diabetes and/or smoking habit. Clin Oral Investig. 2018 May 8. doi: 10.1007/s00784-018-2471-5. [Epub ahead of print].
Tron'ko ND, Zak KP. Obesity and diabetes. Likars'ka sprava. 2013;8(1125):3-21. (in Ukrainian).
Kumar S, Wilson B, Watson L, Alsop J. Obesity is associated with poorer clinical outcomes following insulin initiation for patients with type 2 diabetes. In: Minutes of the 44th Genral Assembly of the European Association for the Study of Diabetes. Diabetologia. 2009;52(Suppl 1):S1-S550. doi: 10.1007/s00125-009-1445-1.
Zak KP, Mankovsky BN, Melnichenko, SV, et al. Immunity in patients with type 2 diabetes mellitus in complex with concomitant metabolic syndrome/obesity - Communication 2: Role of adipocytokines (interleukin-6, tumor necrosis factor alpha, leptin and adiponectin). Endokrynologia. 2013;18(2):26-32. (in Russian).